Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Capital Expenditures: 2013-2024

Historic Capital Expenditures for Fortress Biotech (FBIO) over the last 10 years, with Sep 2024 value amounting to -$1.4 million.

  • Fortress Biotech's Capital Expenditures fell 139600.00% to -$1.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $29,000, marking a year-over-year decrease of 76.98%. This contributed to the annual value of $63,000 for FY2023, which is 97.68% down from last year.
  • According to the latest figures from Q3 2024, Fortress Biotech's Capital Expenditures is -$1.4 million, which was down 200.00% from $1.4 million recorded in Q2 2024.
  • Fortress Biotech's Capital Expenditures' 5-year high stood at $2.0 million during Q4 2021, with a 5-year trough of -$1.4 million in Q3 2024.
  • Over the past 3 years, Fortress Biotech's median Capital Expenditures value was $59,500 (recorded in 2022), while the average stood at $277,800.
  • Within the past 5 years, the most significant YoY rise in Fortress Biotech's Capital Expenditures was 8,618.75% (2024), while the steepest drop was 139,600.00% (2024).
  • Fortress Biotech's Capital Expenditures (Quarterly) stood at $698,000 in 2020, then skyrocketed by 180.37% to $2.0 million in 2021, then tumbled by 95.35% to $91,000 in 2022, then slumped by 69.23% to $28,000 in 2023, then crashed by 139,600.00% to -$1.4 million in 2024.
  • Its Capital Expenditures stands at -$1.4 million for Q3 2024, versus $1.4 million for Q2 2024 and $28,000 for Q4 2023.